Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3147514 | 0.88 | HTR6 (1.00) | HTR6HTR2ASIRT6EGFRHRH4 | |
| SCHEMBL3148347 | 0.88 | HTR6 (1.00) | HTR6HDAC1HDAC8HDAC6HTR2A | |
| SCHEMBL3153311 | 0.82 | HTR6 (1.00) | HTR6HTR2ASIRT6EGFRADRA2B | |
| SCHEMBL3152600 | 0.80 | HTR6 (0.82) | HTR6HTR2ASIRT6EGFRHRH4 | |
| SCHEMBL2483723 | 0.78 | HTR6 (1.00) | HTR6SIRT6MAPT | |
| SCHEMBL24641958 | 0.77 | HTR6 (0.62) | HTR6HTR2AEGFRHRH4ADRA2B | |
| SCHEMBL13225331 | 0.76 | HTR6 (0.64) | HTR6SIRT6EGFRHTR1DALK | |
| SCHEMBL3148639 | 0.76 | HTR6 (1.00) | HTR6HTR2ASIRT6HRH4MEN1 | |
| SCHEMBL30017234 | 0.76 | HTR6 (0.61) | HTR6HTR2AHRH4ADRA2BADRA2C | |
| SCHEMBL24642108 | 0.76 | HTR6 (0.61) | HTR6HTR2AHRH4ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | disclosed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | disclosed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885HDAC1 1319/4885HDAC8 1064/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | HTR6 4/4885HDAC1 1204/4885HDAC8 1153/4885 |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | HTR6, HTR5A, HTR7 | HTR6 1/4885HDAC1 1923/4885HDAC8 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.